WO2005004829A1 - Compostions sous forme de poudre et preparation cutanee contenant celles-ci en vue d'un usage externe - Google Patents
Compostions sous forme de poudre et preparation cutanee contenant celles-ci en vue d'un usage externe Download PDFInfo
- Publication number
- WO2005004829A1 WO2005004829A1 PCT/JP2004/010165 JP2004010165W WO2005004829A1 WO 2005004829 A1 WO2005004829 A1 WO 2005004829A1 JP 2004010165 W JP2004010165 W JP 2004010165W WO 2005004829 A1 WO2005004829 A1 WO 2005004829A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- water
- component
- powdery
- powder
- ascorbic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
Definitions
- TECHNICAL FIELD The present invention relates to a powdery composition which is used by being dispersed in water or a cosmetic containing water at the time of use, and more specifically, has excellent storage stability without causing odor or discoloration over time.
- TECHNICAL FIELD The present invention relates to a powdery composition having good dispersibility in water at the time of use and an external preparation for skin such as cosmetics containing the same. Background art
- ascorbic acid has been used in cosmetics with the expectation of skin effects such as promotion of collagen growth, prevention of skin tissue against external stimuli, suppression of pigmentation, prevention of comedo, and tightening of pores.
- ascorbic acid is an unstable substance that is easily decomposed due to the presence of water, and the color of the cosmetic is changed to brown and odor is generated due to this decomposition.
- ascorbic acid phosphate does not have good dispersibility and solubility in water. Powder cosmetics containing this have problems in usability.
- phosphoric acid ascorbate was not at a satisfactory level with regard to skin effects. This problem could not be completely solved even by using a method of freeze-drying with a water-soluble polymer as described in Japanese Patent Application Laid-Open No. 3-68707.
- ascorbic acid is used by encapsulating it in ribosomes, which are multilamellar vesicles of phospholipids, in order to improve transdermal absorption into the skin and enhance the drug effect (for example, And Japanese Patent Application Laid-Open No. 8-183732.
- the present inventors have made intensive studies in the above situation and found that the above problem can be solved by using ascorbic acid as an alkaline earth metal salt and using it in combination with a phospholipid, and completed the present invention. .
- the present inventors have also found that the above problem can be solved by encapsulating an alkaline earth metal salt of ascorbic acid in ribosomes formed by phospholipids and sterols and pulverizing the same. Was completed.
- the first object of the present invention is to provide at least the following component (a) and component (b)
- a second object of the present invention is to provide the above powdery composition further containing, as component (c), ester sodium ascorbate or magnesium ascorbate.
- a third object of the present invention is to provide a powdery composition which further contains sterols as the component (d) and exhibits a ribosome form when dispersed in water or cosmetics containing water. That is.
- Still another object of the present invention is to provide a skin external preparation such as a cosmetic containing the powdery composition.
- the phospholipid of the component (a) used in the present invention is not particularly limited as long as it is generally used in cosmetics.
- Examples thereof include soybean-derived phospholipids, soybean-derived hydrogenated phospholipids, and soybean-derived phospholipids.
- Lysophospholipid, hydrogenated lysophospholipid derived from soybean, phospholipid derived from egg yolk, hydrogenated phospholipid derived from egg yolk, lysophospholipid derived from egg yolk, hydrogenated lysophospholipid derived from egg yolk, etc. can be used. Seeds or more can be used.
- the use of a hydrogenated phospholipid derived from soybean or a hydrogenated phospholipid derived from egg yolk is preferable because a powdery composition having particularly excellent storage stability can be obtained.
- the content of the component (a) with respect to the entire powdery composition of the present invention is not particularly limited, but is preferably 5 to 90% by mass (hereinafter simply abbreviated as “%”), and particularly preferably 20%. ⁇ 80% is preferred.
- the powdery composition has particularly good dispersibility in water, and can provide a non-sticky feel.
- the alkaline earth metal salt of ascorbic acid as the component (b) used in the present invention, for example, magnesium ascorbate, calcium ascorbate and the like can be used. One or more of these can be used as necessary.
- alkaline earth metal ascorbate As the component (b), a commercially available alkaline earth metal ascorbate may be used, but the alkaline earth metal ascorbate may be formed and used in the step of producing the powdery composition. That is, a compound that dissolves and disperses ascorbic acid or an alkaline earth metal salt in water and generates an alkaline earth metal cation in the water (hereinafter abbreviated as “alkaline earth metal compound”). By adding the same, an alkaline earth metal ascorbate can be formed in the production process of the powdery composition. When the ribosome is formed as described below, an alkaline earth metal ascorbate can be formed in the step of producing the powdery ribosome composition.
- the alkaline earth metal compound is not particularly limited, but is preferably an alkaline earth metal hydroxide, chloride, hydrogen phosphate or sulfate. Specific examples thereof include magnesium hydroxide and hydroxide. Calcium, calcium chloride, magnesium chloride, calcium hydrogen phosphate, magnesium sulfate, and the like. Particularly preferred is magnesium hydroxide or calcium hydroxide. One or more of these can be used as needed. As described later, the powdery composition of the present invention desirably has a pH of 3 to 6 when dissolved and dispersed in water at a concentration of 10%. Incorporation of alkaline earth metal compounds Is preferred.
- the content of the above component (b) with respect to the entire powdery composition of the present invention is not particularly limited, but is preferably from 10 to 70%, particularly preferably from 20 to 50%.
- the powdery composition has particularly good dispersibility in water and can provide a non-sticky feel.
- the powdered composition is a powdered liposome composition as described later, the powdered ribosome composition is also particularly excellent in dispersibility in water, and provides a non-sticky feeling. Can be.
- the “powder ribosome composition” refers to a powder composition that exhibits a ribosome form when dispersed in water or a cosmetic containing water.
- the powdery composition of the present invention may further contain, as component (c), an ascorbic acid derivative other than component (b), whereby the powdery composition can be added to water when used. Can be further improved in dispersibility.
- Ascorbic acid derivatives of component (c) include ascorbic acid phosphate salts such as ascorbate ester magnesium phosphate, ascorbic acid phosphate sodium salt, etc., and ascorbic acid sulfate salts such as sodium ascorbate sulfate. Is mentioned. Particularly preferred is ester magnesium ascorbate or sodium phosphate ascorbate. One or more of these can be used as necessary.
- the content is not particularly limited, but the ratio of the component (b) to the component (c) is 1: 0 by mass ratio. 0.5 to 3 are preferable, and 1: 0.1 to! Is more preferred.
- sterols are added as the component (d) so as to exhibit a ribosome form. That is, it is also preferable that the powdery composition is a powdery ribosome composition.
- the sterols of the component (d) used in the present invention can be used without particular limitation as long as they form a lipid bilayer together with the component (a) in water. Examples thereof include cholesterol and phytosterol. Can be One or two of these can be used as needed.
- the content of the component (d) in the entire powdery composition is not particularly limited, but is preferably from 10 to 40%, more preferably from 15 to 30%, based on the component (a).
- a powdery ribosome composition having particularly excellent storage stability can be prepared.
- the powdery composition of the present invention may contain a powder-forming agent such as dextrin, cyclodextrin, glucose, sorbitol, starch, or cellulose powder, in addition to the above components.
- the powdery composition of the present invention may further comprise, if necessary, a pH adjuster for adjusting the pH when dispersed in water to a concentration of 10% to 3 to 6.
- a pH adjuster for adjusting the pH when dispersed in water to a concentration of 10% to 3 to 6.
- Such pH adjusters are not particularly limited, but preferred examples thereof include citrate, citrate, succinate, succinate, malate, malate, lactic acid, lactate, tartaric acid, tartrate, Phosphoric acid, dihydrogen phosphate, monohydrogen phosphate, phosphate and the like.
- the salt is not particularly limited, but is preferably a sodium salt. One or more of these can be used as needed.
- the content of the pH adjuster in the powdery composition of the present invention is preferably 0.01 to 5% based on the whole powdery composition.
- the powdery composition of the present invention may further comprise an oil, a polyhydric alcohol, a water-soluble polymer, a powder, a surfactant, an ultraviolet absorber, a film-forming agent, and para-hydroxybenzoic acid, if necessary.
- Derivatives or preservatives such as phenoxyethanol, bismuth amines, beauty ingredients, humectants, fragrances, bactericides, pigments, antioxidants, and the like can be contained.
- the method for producing the powdery composition of the present invention using each of the above components is not particularly limited, but a method of freeze-drying a liquid in which each component is dissolved or dispersed in water is preferable. Specifically, in addition to component (a) and component (b),
- powdery composition of the present invention is uniformly dispersed by a high-speed stirrer and freeze-dried at a temperature of, for example, 20 ° (: 0.05 to 0.5 torr (6 to 70 Pa)) for 24 hours. Manufactured.
- the powdery composition is a powdery liposome composition
- a method for dissolving or dispersing each component in water, once preparing a liposome in water, and freeze-drying the liquid is preferred. It is suitable.
- the powdery composition of the present invention produced as described above has a storage stability at 20 ° C. when the pH when dispersed in water at a concentration of 10% is in the range of 3 to 6. It is preferable because the property is particularly good.
- the powdery composition of the present invention obtained as described above can be used alone as an external preparation for the skin such as cosmetics and quasi-drugs, but it can be added to other ingredients to make up the cosmetic composition. It can also be used as an external preparation for skin such as cosmetics and quasi-drugs.
- oils examples include oils, ultraviolet absorbents, preservatives such as paraoxybenzoic acid derivatives or phenoxyethanol, biquinones, beauty ingredients, humectants, Perfumes, bactericides, pigments, antioxidants, and the like.
- preservatives such as paraoxybenzoic acid derivatives or phenoxyethanol
- biquinones beauty ingredients
- humectants e.g., glycerol, bactericides, pigments, antioxidants, and the like.
- the content of these other components is preferably 50% or less based on the whole skin external preparation.
- the powder composition of the present invention and the external preparation for skin containing the same are powders, which are used by dispersing in water or cosmetics containing water (hereinafter abbreviated as “water etc.”). It is.
- This dispersion can be impregnated into a nonwoven fabric or the like and applied to the skin for use, or can be directly applied by hand and used.
- the mixing ratio of the skin external preparation to water and the like at the time of use is not particularly limited, but is preferably from 1: 1 to 49, more preferably from 1: 4 to 19 by mass ratio. When the mixing ratio with water or the like is within this range, the dispersibility in water or the like is good, and usability without stickiness can be secured.
- the powdery composition of the present invention described above despite containing ascorbic acid, has excellent storage stability without causing discoloration or discoloration over time, and has good solubility in water when used. Things. Therefore, when it is used by directly dispersing it in water, etc., it is expected to have a good feeling of use and to have skin effects such as promotion of collagen growth possessed by ascorbic acid, protection of skin tissue against external stimuli, and suppression of pigmentation. You can do it.
- this powdery composition is dispersed in water or a cosmetic containing water to prepare a quasi-drug or a skin external preparation such as a whitening cosmetic, a serum, a lotion, an emulsion or a basic cosmetic such as a pack. Also, the skin effect as described above is expected.
- A Components 2 to 5, component 8 and component 9 were dissolved in 1000 parts by mass of purified water.
- B Component 1, Component 6 and Component 7 were added to A and heated to 70 ° C.
- B was uniformly dispersed with a high-pressure homogenizer.
- E D was filled in a closed container to obtain a powder cosmetic.
- Inventive products 1 to 7 and comparative products 1 and 2 each with a makeup history of 10 women over 10 years as a panel. Add purified water, mix well with fingers and apply to the face.Each panel gives a score for each cosmetic according to the following criteria B, and calculates the average score of all panels. Judgment was made according to Standard C.
- a powder cosmetic was produced by the following production method.
- ⁇ Components 4 to 8 were mixed with 500 parts by mass of purified water.
- B Components 1-3 were added to A and heated to 70 ° C.
- B was uniformly dispersed with a high-pressure homogenizer.
- E D was filled in a closed container to obtain a powder cosmetic.
- the pH of the solution obtained by dispersing the obtained cosmetic powder in water at a concentration of 10% was 4.5.
- This powder cosmetic was used as a lotion by adding 19 parts by mass of purified water to 1 part by mass of the cosmetic, and mixing the resulting mixture sufficiently.
- the storage stability, dispersibility in water, and usability were evaluated in the same manner as in Example 1, and the resulting powder cosmetic was excellent in storage stability and dispersed in water. The properties were good, and the product had a good usability.
- a powder cosmetic was produced by the following production method.
- Components 3 to 10 were mixed with 300 parts by mass of purified water.
- B was uniformly dispersed with a high-pressure homogenizer.
- D was filled in a closed container to obtain a powder cosmetic.
- the pH of the liquid in which the obtained powder cosmetic was dispersed at a concentration of 10% in water was 5.0.
- This powder cosmetic was used as a serum by adding 40 parts by weight of a lotion having the following composition to 10 parts by weight of the cosmetic and thoroughly mixing.
- the obtained cosmetic powder had excellent storage stability and was dispersed in water. The properties were good and the user had a good feeling in use.
- Components 4 to 8 were mixed with 300 parts by mass of purified water.
- B was uniformly dispersed with a high-pressure homogenizer.
- E D was filled in a closed container to obtain a powder cosmetic.
- the pH of the liquid in which the obtained powder cosmetic was dispersed at a 10% concentration in water was 4.3.
- This powder cosmetic was used as a pack by adding 19 parts by mass of purified water to 1 part by mass of the cosmetic, thoroughly mixing and impregnating the nonwoven fabric.
- the storage stability, dispersibility in water, and usability were evaluated in the same manner as in Example 1, and the resulting cosmetic powder had excellent storage stability and was dispersed in water. The properties were good, and a good feeling of use was obtained.
- Example 5 Using the components shown in Table 3 as raw materials, powder cosmetics (Invention products 8 to 19 and Comparative products 3 to 5) were prepared by the following production method.
- the pH, storage stability, dispersibility in water, and feeling of use of a 10% aqueous solution or dispersion were measured and evaluated in the same manner as in Example 1. did. Table 4 shows the results.
- Components 4 to 7, Component 11 and Component 12 were dissolved in 100 parts by mass of purified water.
- B was uniformly dispersed with a high-pressure homogenizer.
- E D was filled in a closed container to obtain a powder cosmetic.
- a powder cosmetic was obtained by the following production method.
- Components 4 to 8 were mixed with 500 parts by mass of purified water.
- B was uniformly dispersed with a high-pressure homogenizer.
- E D was filled in a closed container to obtain a powder cosmetic.
- the pH of the obtained powder cosmetic was measured in the same manner as in Example 1, and it was 4.5.
- This powder cosmetic was used as a lotion by adding 190 parts by mass of purified water to 10 parts by mass of the cosmetic and thoroughly mixing. Also, as in the first embodiment When the following items were evaluated for storage stability, dispersibility in water, and feeling of use, the obtained cosmetic powder had excellent storage stability and good and good dispersibility in water. Had a good feeling of use.
- Example 7
- a powder cosmetic was obtained by the following production method.
- Components 3 to 10 were mixed with 300 parts by mass of purified water.
- B was uniformly dispersed with a high-pressure homogenizer.
- This powder cosmetic was used as a serum by adding 4 parts of a lotion having the following composition to 10 parts by mass of the cosmetic and thoroughly mixing.
- Lotion composition
- Example 8 Remaining purified water The storage stability, dispersibility in water, and feeling of use were evaluated in the same manner as in Example 1. The powder cosmetics obtained had excellent storage stability. However, the dispersibility in water was good, and a good feeling of use was obtained. Example 8
- a powder cosmetic was obtained by the following production method.
- Components 4 to 8 were mixed with 300 parts by mass of purified water.
- B was uniformly dispersed with a high-pressure homogenizer.
- Example 1 D was filled in a closed container to obtain a powder cosmetic.
- the pH of the obtained powder cosmetic was measured in the same manner as in Example 1, and it was 4.3.
- This powder cosmetic was used as a pack by adding 190 parts by mass of purified water to 10 parts by mass of the cosmetic, sufficiently mixing and impregnating the nonwoven fabric.
- the obtained powder cosmetic was excellent in storage stability, good in dispersibility in water, and had a good feeling in use.
- ADVANTAGE OF THE INVENTION while containing ascorbic acid, it is excellent in storage stability without discoloration and discoloration over time, and has good dispersibility in water at the time of use.
- An external preparation for skin can be provided.
- the above-mentioned excellent effects can be obtained even when the powdery composition is used as a powdery ribosome composition.
- the present invention can be widely used in the field of skin external preparations such as cosmetics.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005511594A JPWO2005004829A1 (ja) | 2003-07-10 | 2004-07-09 | 粉末状組成物およびこれを含有する皮膚外用剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-194943 | 2003-07-10 | ||
JP2003-194942 | 2003-07-10 | ||
JP2003194942 | 2003-07-10 | ||
JP2003194943 | 2003-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005004829A1 true WO2005004829A1 (fr) | 2005-01-20 |
Family
ID=34067327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/010165 WO2005004829A1 (fr) | 2003-07-10 | 2004-07-09 | Compostions sous forme de poudre et preparation cutanee contenant celles-ci en vue d'un usage externe |
Country Status (4)
Country | Link |
---|---|
JP (1) | JPWO2005004829A1 (fr) |
KR (1) | KR20060040662A (fr) |
TW (1) | TW200507879A (fr) |
WO (1) | WO2005004829A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008531682A (ja) * | 2005-02-28 | 2008-08-14 | ソンヒョン チェ | 血清タンパク質の浸出を減少させる組成物 |
JP2010180193A (ja) * | 2009-02-09 | 2010-08-19 | Fine Co Ltd | 高品質化粧料 |
US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
US11110049B2 (en) | 2017-06-23 | 2021-09-07 | The Procter & Gamble Company | Composition and method for improving the appearance of skin |
US11583488B2 (en) | 2020-06-01 | 2023-02-21 | The Procter & Gamble Company | Method of improving penetration of a vitamin B3 compound into skin |
US11622963B2 (en) | 2018-07-03 | 2023-04-11 | The Procter & Gamble Company | Method of treating a skin condition |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62201893A (ja) * | 1986-03-03 | 1987-09-05 | Mitsuo Matsumoto | アスコルビン酸−ホスフアチジルコリン結合物 |
JPH0276868A (ja) * | 1987-10-19 | 1990-03-16 | Takeda Chem Ind Ltd | 安定なアスコルビン酸組成物および粉末の製造法 |
JPH02276551A (ja) * | 1989-01-27 | 1990-11-13 | Takeda Chem Ind Ltd | 被覆製剤およびその用途 |
JPH03181491A (ja) * | 1989-12-11 | 1991-08-07 | Nippon Saafuakutanto Kogyo Kk | 水分散性レシチン |
JPH0525042A (ja) * | 1990-12-21 | 1993-02-02 | Takeda Chem Ind Ltd | 水溶性ビタミン類を含有する組成物 |
JPH10203964A (ja) * | 1997-01-16 | 1998-08-04 | Lipotec Sa | 難吸収性薬剤の経口生物学的利用能を改善する新しい調剤 |
JP2001278811A (ja) * | 2000-03-29 | 2001-10-10 | Nonogawa Shoji Kk | 皮膚外用剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004244319A (ja) * | 2003-02-10 | 2004-09-02 | Nippon Fine Chem Co Ltd | 化粧料及び皮膚外用剤 |
-
2004
- 2004-07-08 TW TW093120491A patent/TW200507879A/zh not_active IP Right Cessation
- 2004-07-09 KR KR1020067000421A patent/KR20060040662A/ko not_active Application Discontinuation
- 2004-07-09 WO PCT/JP2004/010165 patent/WO2005004829A1/fr active Application Filing
- 2004-07-09 JP JP2005511594A patent/JPWO2005004829A1/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62201893A (ja) * | 1986-03-03 | 1987-09-05 | Mitsuo Matsumoto | アスコルビン酸−ホスフアチジルコリン結合物 |
JPH0276868A (ja) * | 1987-10-19 | 1990-03-16 | Takeda Chem Ind Ltd | 安定なアスコルビン酸組成物および粉末の製造法 |
JPH02276551A (ja) * | 1989-01-27 | 1990-11-13 | Takeda Chem Ind Ltd | 被覆製剤およびその用途 |
JPH03181491A (ja) * | 1989-12-11 | 1991-08-07 | Nippon Saafuakutanto Kogyo Kk | 水分散性レシチン |
JPH0525042A (ja) * | 1990-12-21 | 1993-02-02 | Takeda Chem Ind Ltd | 水溶性ビタミン類を含有する組成物 |
JPH10203964A (ja) * | 1997-01-16 | 1998-08-04 | Lipotec Sa | 難吸収性薬剤の経口生物学的利用能を改善する新しい調剤 |
JP2001278811A (ja) * | 2000-03-29 | 2001-10-10 | Nonogawa Shoji Kk | 皮膚外用剤 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008531682A (ja) * | 2005-02-28 | 2008-08-14 | ソンヒョン チェ | 血清タンパク質の浸出を減少させる組成物 |
JP2012188434A (ja) * | 2005-02-28 | 2012-10-04 | Seong-Hyun Choi | 血清タンパク質の浸出を減少させる組成物 |
US8853195B2 (en) | 2005-02-28 | 2014-10-07 | Kt & G Corporation | Composition for reducing the exudation of serum proteins |
JP2010180193A (ja) * | 2009-02-09 | 2010-08-19 | Fine Co Ltd | 高品質化粧料 |
US11110049B2 (en) | 2017-06-23 | 2021-09-07 | The Procter & Gamble Company | Composition and method for improving the appearance of skin |
US11622963B2 (en) | 2018-07-03 | 2023-04-11 | The Procter & Gamble Company | Method of treating a skin condition |
US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
US11583488B2 (en) | 2020-06-01 | 2023-02-21 | The Procter & Gamble Company | Method of improving penetration of a vitamin B3 compound into skin |
US11911498B2 (en) | 2020-06-01 | 2024-02-27 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
Also Published As
Publication number | Publication date |
---|---|
TWI335824B (fr) | 2011-01-11 |
TW200507879A (en) | 2005-03-01 |
JPWO2005004829A1 (ja) | 2006-08-24 |
KR20060040662A (ko) | 2006-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5064717B2 (ja) | リポソーム及びリポソーム含有化粧料 | |
JP5969793B2 (ja) | アスコルビン酸誘導体が配合されたリポソーム組成物 | |
WO1998056338A1 (fr) | Produit cosmetique eclaircissant la peau | |
JP2014208626A (ja) | リポソーム組成物 | |
JP4304352B2 (ja) | ソホロリピッドを含む経皮吸収制御剤及びその製造方法 | |
TW201116303A (en) | Composition for alleviating ultraviolet radiation-induced damage | |
JP3770884B2 (ja) | 美白剤 | |
WO2005004829A1 (fr) | Compostions sous forme de poudre et preparation cutanee contenant celles-ci en vue d'un usage externe | |
KR101465109B1 (ko) | 단시간에 피부 탄력을 증진시키고 피부 주름을 개선시키는 화장료 조성물 및 그 제조 방법 | |
KR20110072022A (ko) | 성상 변화를 갖는 화장료 조성물 | |
JP5198899B2 (ja) | 細胞賦活剤及び老化防止用皮膚外用剤 | |
CN109890361B (zh) | 含有亚油酸的组合物 | |
JP4814675B2 (ja) | 皮膚外用剤 | |
JP5138880B2 (ja) | 美白用組成物 | |
KR101261388B1 (ko) | 소듐폴리감마글루타메이트의 효능향상을 위한 조성물 및 이의 캡슐화 방법 및 이를 포함하는 화장료 조성물 | |
JPH10114897A (ja) | 粉末香料、その製造方法及びその応用 | |
JP2004352643A (ja) | ゲル状化粧料 | |
JP4740015B2 (ja) | 2剤混合型皮膚外用剤 | |
JP5437552B2 (ja) | 2剤混合型皮膚外用剤 | |
WO2024095311A1 (fr) | Composé contenant un dérivé d'acide ascorbique | |
JP4001310B2 (ja) | 脂質複合体及びこれを含有する外用組成物 | |
CN100496453C (zh) | 粉末状组合物和含有该组合物的皮肤外用剂 | |
JP2001199865A (ja) | 美白化粧料 | |
JPH08143422A (ja) | 複合粉体及び複合粉体含有化粧料 | |
KR20130057634A (ko) | Egcg의 안정화 방법 및 egcg를 함유하는 피부 미백용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480025586.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005511594 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067000421 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067000421 Country of ref document: KR |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
122 | Ep: pct application non-entry in european phase |